PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

Purpose

This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample. Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System. Treating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician. Total duration of study is anticipated to be approximately 6 months.

Conditions

  • Helicobacter Pylori
  • Safety
  • Efficacy

Eligibility

Eligible Ages
Between 3 Years and 17 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Male or female age 3-17 at the time of visit - Subject/Legal guardian (and subject when relevant) is willing to sing the Informed Consent/Assent Form - Naive to H. pylori treatment in the past 4 weeks

Exclusion Criteria

  • Pregnant and/or lactating women - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient of the quality of data - Participation in other interventional trials - Allergy to test substrates - Antibiotics taken within 4 weeks of the testing - Study subjects shall not consume the following items at least 1 hour prior to the PPUBT test: Mouthwash, Chewing Gum, Carbonated Beverages, Cigarette Smoke, Acetone (to simulate the effect of ketone production that may result from some diets), Alcohol, Food - Children 12 years and older - to be excluded after a written notification from the sponsor is received at the site that the limit of (approx.) 1/3 of the sample size was achieved for this group

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Indication for H. pylori testing 		Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
  • Combination Product: PyloPlus Urea Breath Test System
    System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
  • Diagnostic Test: Stool Antigen Test
    An antigen test performed via a laboratory to test patients' stool for H. pylori

Recruiting Locations

Dolphin Medical Research
Doral, Florida 33172
Contact:
Fermin Nieto
305-870-5999

Orlando Health, Inc.
Orlando, Florida 32806
Contact:
Yazandra Parrimon, RN

Harmony United Research
El Paso, Texas 79902
Contact:
Arthur Imai
915-519-5297

More Details

Status
Recruiting
Sponsor
ARJ Medical, Inc.

Study Contact

Clinical Trial Manager
877-855-4100
info@gulfcoastscientific.com